ROTES GOLD HEMOSOL - 500 Beiträge pro Seite

[Big Charly]

Just in case you missed it the first time.

2003-12-05 06:38 ET - In the News
Also In the News (C-PLI) ProMetic Life Sciences Inc


The Globe and Mail reports in its Friday, Dec. 5, edition that two Canadian biotech companies and the American Red Cross are joining forces to retrofit an idle plant owned by Hemosol in Mississauga and establish the country`s first blood plasma plant for the production of valuable medical proteins. The Globe`s Leonard Zehr writes that under the accord, Hemosol will initially process 500,000 litres of blood plasma a year supplied by the ARC, using a new Cascade technology developed jointly by ProMetic Life Sciences and the ARC. "This alliance will offer important benefits to all three organizations, as well as to all North Americans since this plant will provide life-saving medicines at lower costs, in accordance with required safety measures," said ProMetic chief executive officer Pierre Laurin. While the agreement envisages an expansion to process up to one million litres of ARC plasma a year, Hemosol CEO Lee Hartwell said 500,000 litres "is more than enough to make this plant profitable." An unnamed source says Hemosol is expected to generate revenues of $200 to $300 for each litre of plasma processed, depending on the number of proteins recovered with the Cascade technology.


.

[franzwerner]

Verstehe das Thema - rotes Gold nicht. Die Farbe rot ist ja wohl dem Hämoglobin zugedacht- dieser Fall ist wohl eher gelb (Plasma).
Offensichtlich suchen die Herrschaften ihr Glück in der Flucht nach vorne. Der Glaube in die Entwicklung eines Sauerstoffträgers ist wohl mehr als getrübt.
Nun die befinden sich mit Ihren Hb- Derivaten ja in guter Gesellschaft mit BPUR.
Nun ein kurzes Lebenszeichen kann es ja gewesen sein, aber..........

[XQC]

...aber...aber...laber...laber...
schaun ma mal...

[XQC]

nasdaq im moment ueber 13mio. gehandelte stk.
kann sein das die heute noch runterkommt, aber mir egal ich fasse die (wie die lezten 4jahre auch) nicht an!
hier was zum lesen...

Business Story

Hemosol rockets after ProMetic deal

CRAIG WONG
CP


Friday, December 05, 2003

Hemosol`s processing facility in Mississauga, Ont., received a new lease on life through the licensing agreement announced yesterday with ProMetic. Hemosol CEO Lee Hartwell is at the Mississauga plant, which has been left idle because of problems with the firm`s artificial-blood products.

CREDIT: CP

ADVERTISEMENT



Shares in Hemosol Inc. rose 82 per cent yesterday as the company arranged an infusion of work for its new plant west of Toronto, left idle by problems with its artificial-blood product.

The agreement with ProMetic Life Sciences Inc. involves about $18 million in cash and Hemosol stock.

Hemosol`s shares rose 74 cents to $1.64 in Toronto trading yesterday. They traded at more than $25 in 2000.

The companies said Hemosol is obtaining an exclusive North American licence for a new so-called cascade purification process developed by Montreal-based ProMetic and the American Red Cross to recover proteins from human plasma.

The process will be instituted at Hemosol`s $90-million Meadowpine facility in Mississauga, Ont., with raw material supplied by the American Red Cross.

The cascade process is said to "significantly improve the yield and product recovery of valuable proteins isolated from human plasma" compared with established fractionation techniques.

Hemosol has issued 2 million shares to ProMetic with the signing of a binding memorandum of understanding, and will issue another one million shares and pay $1.5 million in cash when a definitive agreement is reached.

Hemosol will pay the remainder of the deal over the next three to four years, plus royalties of five to eight per cent to ProMetic on the sale of products isolated using the process.

ProMetic shares slipped 2 cents to $1.95.

© Copyright 2003 Montreal Gazette

gruss und allen (hauptsaechlich charly) ein schoenes we
XQC

[franzwerner]

MISSISSAUGA — There`s an eerie silence interrupted only by the hum of overhead lighting when you walk through Hemosol Inc.`s manufacturing plant.

Gleaming white walls and spotless floors surround shiny, stainless steel vats, which should be converting outdated blood into a synthetic substitute called Hemolink.

But the loading bays are empty at the $90-million plant and nobody is manning the brand-spanking-new machinery, which sits idle.

That`s because after an impressive clinical track record as a replacement for blood transfusions, Hemolink`s safety was thrown into question in March when it suddenly failed in tests with cardiac patients, prompting the cash-starved company to hunker down in survival mode.

All that is about to change.

Rather than sell the plant and return to early-stage drug development, Hemosol`s new president and chief executive officer Lee Hartwell convinced the board to use the plant to manufacture new biologic drugs, particularly blood-related proteins, for other companies that need batch quantities for clinical trials.

"We`ve targeted 50 companies, of which we`re talking to a dozen, and five are very serious," he said.

One proposal on the table would represent revenue of $6-million (U.S.) in a contract that would use a small portion of the plant for six to nine months, he said.

"We discovered there`s a scarcity of these types of plants around the world and we have expertise in engineering and quality control," he said.

"And there are a lot of biologics moving into Phase II and III, so we can save companies money by doing the manufacturing for them, which could get them to market faster."

In two to three years, he figures the plant could be generating annual revenue of $25-million to $50-million (Canadian) from traditional contract manufacturing relationships, including longer-term deals with European drug makers that want access to a North American plant as a fast way to get to market.

"The white elephant people talked about is really a great asset," he said, referring to investor criticism that the company built a plant to make 300,000 units of Hemolink a year before it even finished clinical testing.

"Revenue from the plant is going to help us offset [research spending] on the products we have in our pipeline."

Mr. Hartwell`s strategy also includes possible strategic partnerships with drug developers that would bring their own technology into the plant to manufacture a new product. "The potential here is upwards of $200-million [a year]," he added.

Hemosol`s manufacturing team also plans to showcase the plant at several upcoming biotech trade shows for prospective clients. Even blood substitute competitor Biopure Corp. of Cambridge, Mass., looked at buying the plant but "couldn`t afford it," Mr. Hartwell acknowledged.

But he was adamant that the company isn`t abandoning Hemolink.

"We`re keeping the processing equipment and it may take us longer, but we`re a lead player [in oxygen therapeutics] and still believe there`s a huge market potential."

On Friday, the company completed the sale of $5.9-million of special warrants, which should keep it afloat until mid-2004 when manufacturing revenues kick in.

About $1-million is earmarked to complete an analysis of Hemolink, which has already gobbled up $300-million of R&D, with the objective of getting it off clinical hold.


Nun im Immobilien - und Dienstleistungsgeschäft lässt sich ja auch Geld machen. Man muss sich ja nicht unbedingt auf seinem eher hoffnungslosen Kerngeschäft bewegen.
Kenne nicht viele Firmen die mit dem RK jemals einen kongenialen Partner an Land gezogen haben - teilen ist angesagt.

[Big Charly]

http://www.stockhouse.ca/bullboards/viewmessage.asp?no=70586…

December 8, 2003
It`s been a roller-coaster

JUDY STEED(Toronto Star)

High stakes, blockbuster drugs, critical advances in human health, costly failures — these are the peaks and valleys of biotech pharmaceutical ventures.

How risky is the game?

Three hot prospects tell the tale, revisited within a year of pitching their vision to @Biz:Francesco Bellini`s Neurochem Inc. had a feather in its cap, Alzhemed, a promising treatment for Alzheimer`s disease that had been 25 years in the making by three scientists at Queen`s University. When I talked to Bellini last year at his elegant Montreal headquarters overlooking Victoria Square, the stock was at $3 and the drug a long way from market. The story was published on Sept. 23, 2002. Today, the stock is above $20. What`s the excitement about?"Hemolink is the best hemoglobin-based oxygen carrier," the head of the U.S. Naval Blood Research Lab told me a year ago. The story was published on Dec. 16, 2002. Hemosol`s stock had hit a high of $27 in February 2000, just before the tech bubble burst, and hopes were high for this unique Canadian technology. But as a phase II clinical trial was nearing completion in the U.S. this year, concerns about Hemolink were raised, the trial halted and Hemosol`s state-of-the-art $90 million facility in Mississauga, revved up to produce its first batch of commercial Hemolink, almost shut down. Can this company be saved?

The bad news came in an e-mail, just when construction of Hemosol`s manufacturing plant was being completed, within a few months of producing the first clinical batches of Hemolink at commercial scale.

It was March, 2003. Lee Hartwell, then CFO and vice-president of corporate development, was just back from vacation. "I was excited. Clinical trials were almost at an end, we were near the goal line. Then we got the message. ``They (a group of independent medical data monitors) wanted us to halt the trial."

No one died or suffered severe harm from Hemolink used in cardiac bypass surgery in the U.S., but there was evidence in some patients of "elevated enzymes" that indicated myocardial infarction, a problem that needed investigation, especially since Hemolink is going where no one has gone before, creating an entirely new product category. The result: "Ten years of work, in 24 hours, everything came to a halt," Hartwell says.

The chief executive, John Kennedy, a molecular biologist turned corporate leader, had been diagnosed with cancer before Christmas and was off work when Hartwell called him, to give him the bad news. Kennedy insisted on coming in to tell the staff what had happened. There wasn`t a dry eye in the place.

"He was a passionate man," says John Rydall, director of manufacturing operations, who helped design and build the plant. "He believed Hemolink would save lives, he believed we`d get there."

Kennedy didn`t make it — he died in June — but the company might get there.

Its investors hope so.


--------------------------------------------------------------------------------
In Hemosol`s case, the world`s largest, most sophisticated manufacturing operation of its kind sits still. Maybe not for long
--------------------------------------------------------------------------------


MDS Inc., Hemosol`s largest single shareholder, owns 23 per cent of the firm and invested $25 million before Hemosol went public in 1993.

Since then, more than $312 million was raised on public markets and invested in Hemosol.

Unhappy investors are legion. Sometimes they even show up on the doorstep. One was so angry that Hartwell — who took over as chief executive from Kennedy — insisted the man calm down before Hartwell took him on a tour to show him where the money had gone. "He felt better knowing we hadn`t blown it on lifestyle," Hartwell says wryly. "No gold plated washrooms."

Indeed. The front office is spare, bare bones. The plant is vast — and deserted. The world`s largest, most sophisticated manufacturing operation of its kind sits still.

Of 155 staff, only 35 remain.

Enormous chambers full of fantastically complex, custom- designed equipment gleam in the silence.

On a tour, Hartwell talks of what could be.

"This plant could produce 300,000 units (of Hemolink) a year. Ultimately, we have a program to grow our own hemoglobin — the holy grail." (Hemolink is based on outdated human hemoglobin that is ultra-purified.)

Hartwell is busy raising money and restructuring the business to generate revenues through contract manufacturing.

"We still believe in our lead product, and we`re already well on our way to solving the problem. We think we know what the mechanism is. We will run further animal studies and present the data to the FDA in the fourth quarter of 2004. Our goal is to prove it out, to get the product off `clinical hold.` "

In the meantime, Hemosol has a new business model. "We`ve got drug development expertise and a unique plant that`s second to none. There are a lot of Canadian companies that could get to market faster, and save money, by coming to us."

Just last week, the good news that drove the stock surge: Hemosol announced on Thursday an alliance with ProMetic Life Sciences Inc. of Montreal, which has developed a new technology with the American Red Cross for plasma separation and extraction of new proteins from blood.

"ProMetic brings the technology," Hartwell says, "we bring the manufacturing expertise and the American Red Cross gives us a customer."

The Hemosol plant has the capacity to produce $250 million worth of blood protein annually for the American Red Cross — "but it won`t happen tomorrow," Hartwell says.

What has Hartwell learned?
"It`s a long road," he says. "Longer than you think."

"More testing is required and revenues won`t start to flow until late `04."

He`s talking to Hemosol, he says, about carrying out the actual production process; the final decision has not yet been made. "Hemosol`s facility is unbelievable," he adds. "They`ve been criticized for building it, but they did the right thing. There`s a real unmet need in that area — biologics manufacturing — and it`s extremely complex."

He adds — in case anyone missed the import of it — what a huge coup Hemosol has pulled off in acquiring the American Red Cross as a customer. "That`s a very big customer. That`s a customer for life." Especially with the expected innovation in blood products in the next decade — with Hemosol poised on the leading edge of both research and manufacturing.









«

[Big Charly]

Stock Market Ratings by StockPickReport.com for Microsoft, Hemosol, Newmont Mining, McDonalds, International Paper



SHREVEPORT, La.--(BUSINESS WIRE)--Dec. 8,
2003--StockPickReport.Com (IARD#119079)
http://www.stockpickreport.com/?src=bwtop makes these short-term stock
recommendations:

Microsoft Corp.(NASDAQ-NMS:MSFT)
(Nasdaq:MSFT) - BUY
http://www.stockpickreport.com/rating.php?sym=MSFT&src=#SRC#
////////////////////////////////////////
Hemosol Inc.(NASDAQ-NMS:HMSL)
(Nasdaq:HMSL) - WEAK BUY
///////////////////////////////////////////////////
http://www.stockpickreport.com/rating.php?sym=HMSL&src=#SRC#
Newmont Mining Corp.(NYSE:NEM)
(NYSE:NEM) - STRONG SELL
http://www.stockpickreport.com/rating.php?sym=NEM&src=#SRC#
McDonalds(NYSE:MCD)
Corp. (NYSE:MCD) - BUY
http://www.stockpickreport.com/rating.php?sym=MCD&src=#SRC#
International Paper Co.(NYSE:IP)
(NYSE:IP) - WEAK BUY
http://www.stockpickreport.com/rating.php?sym=IP&src=#SRC#


If you`d like a complete list of all of our STRONG BUY stocks

[XQC]

was soll das?
ich weis es jedenfalls nicht?
hier:


Hemosol Inc. Quick Quote: HML 1.63 (Even)




Net Asset Value Report December 1, 2003
12/9/03

Managed by MDS Capital Corp. which targets $1 billion towards
building companies in the health and life sciences sector.



Net Asset Value:

As of December 1, 2003 the net asset value (NAV) of The Health Care and Biotechnology Venture Fund (the `Fund`) totals $6.9 million or $1.55 per Trust Unit. Twenty-nine percent of the Fund`s investments, including warrants, are currently held in private companies. All of the Fund`s investments are valued in accordance with the Fund`s valuation policy, which is fully described in the notes to the audited financial statements included in the Fund`s annual report. As of December 1, 2003 units in the Fund traded on the TSX at $1.45 per unit, which is a 6% discount to the current net asset value.

Total Per Trust (millions) Unit Cash $ 4.6 $1.03 Investments $ 4.0 $0.90 Provision for Performance Fees ($ 1.7) ($0.38) Total Net Assets $ 6.9 $1.55


Existing Investments:

In December 2003, Hemosol Inc. (NASDAQ:HMSL, TSX:HML) announced that it forged the principle terms of a strategic alliance with ProMetic Biosciences Ltd. a wholly owned subsidiary of ProMetic Life Sciences Inc. (TSX:PLI) that will include Hemosol in-licensing the novel plasma separation technology developed by ProMetic and its strategic partner, the American Red Cross. Hemosol will obtain from ProMetic the exclusive North American license for the novel cascade purification process developed by ProMetic and the American Red Cross (the `Cascade`) to recover valuable proteins from human plasma. Hemosol will implement and optimise the Cascade at Hemosol`s state-of-the-art Meadowpine manufacturing facility. To date the Fund has sold 50% of its position in Hemosol and realized a loss of $1.3 million. On December 1, 2003 the market value of the remainder of this investment (before this announcement was released) was $195,000.



CONTACT: TEL: [phone] Michael Callaghan, Eric Fredrickson

MDS Capital, ext. 6630

EMAIL: [e-mail]

INET: www.mdscapital.com





Gruss XQC

[Big Charly]

Hallo,

Am 1. Dezember 2003 der Markt-Wert vom Rest dieser Anlage (, bevor diese Ankündigung befreit wurde,) war $195,000.

Hier lese ich heraus das MDS vor der Bekanntgabe des Deals verkauft hat.

Anbei noch ein Bericht über einen Plasmahersteller aus Finanzundwirtschaft. Welches Potenzial der Plasmamarkt hat.

Samstag, 13.12.03, 10:58 Uhr
Erscheinungsdatum: 13.12.2003
Ausgabe: 99 finazundwirtschaft


Australische CSL übernimmt Aventis Behring
Gigant im Plasmageschäft entsteht

Die Aktien des Pharmaunternehmens CSL verzeichneten nach der Übernahmeankündigung von Aventis Behring eine Kurssteigerung von zeitweise über 6%. Die Transaktion wird CSL je nach zukünftigem Aktienkurs zwischen 675 und 925 Mio. US-$ kosten. Bis 2007 soll der Handel abgeschlossen sein. Sowohl die Deutsche Bank als auch Merrill Lynch erhöhten das Investment-Rating für CSL diese Woche auf «Kaufen».
Bereits im September 2000 akquirierte das auf Blutprodukte und Impfstoffe spezialisierte Unternehmen das damalige Zentrallaboratorium Bern. Die seither unter dem Namen ZLB Bioplasma firmierende Gesellschaft entwickelt und vertreibt international Medikamente aus Plasma, dem von zellulären Anteilen befreiten Serum des Blutes. ZLB Bioplasma gilt als wichtigster Aktivposten im Portefeuille von CSL und erwirtschaftete im Geschäftsjahr 2002/03 (Ende Juni) einen Umsatz von knapp 400 Mio. US-$. Gegenüber dem Vorjahr musste eine deutliche Einbusse von 16% verzeichnet werden. Die Verkäufe der CSL-Gruppe betrugen in der vergangenen Rechnungsperiode 1,3 Mrd. US-$.

In den letzten zwei Jahren führte ein Überangebot auf dem Markt für Blutprodukte zu einer Reduktion der Preise um rund ein Fünftel. Baxter International, derweltweit führende Plasmahersteller, musste aus Kostengründen die Belegschaft abbauen sowie mehrere Blutspendezentren schliessen. Ausserdem ist von Bayer bekannt, dass die Plasmasparte veräussert werden soll.

Das Pharmaunternehmen CSL plant eine Fusion zwischen ZLB Bioplasma und der neu erworbenen Aventis Behring. Letztere zählt zu den führenden Produzenten von Blutplasma und wies im Jahr 2002 einen Umsatz von 1 Mrd. Euro auf. Von der neuen Gesellschaft mit dem Namen ZLB Behring verspricht sich CSL-Konzernchef Brian McNamee eine Vervollständigung des Produktsortiments sowie jährliche Kosteneinsparungen von über 100 Mio. US-$. Die Akquisition soll die Einnahmen der CSL-Gruppe verdoppeln und dem Konzern zu einem über 20%igen Marktanteil im globalen Plasmageschäft verhelfen. Ob der Hauptsitz der ZLB Behring in Bern sein wird, ist noch unklar.

Auch das Brokerhaus Smith Barney beurteilt die Zusammenlegung der beiden Gesellschaften als eine Verbesserung der Marktposition von CSL. Unter den gegenwärtigen Marktbedingungen sei das jedoch kein entscheidender Vorteil.CG

[reno11]

gomezs!!!

Was ist los mit der "Kursrakete"?
Zuerst groß gepusht, jetzt kommt von "Gomezs" kein
Kommentar?
Alles Kacke oder?
Rene

[franzwerner]

@reno

Die Megaexplosion war auch nicht zu erwarten.
Noch einmal: Frustranes Kerngeschäft, Verlagerung der Prodktionsstätten in Richtung Plasmageschäft, miese finanzielle Lage.


Stammt von "BigCharly" - vielleicht etwas aus dem Kontext:

In den letzten zwei Jahren führte ein Überangebot auf dem Markt für Blutprodukte zu einer Reduktion der Preise um rund ein Fünftel. Baxter International, derweltweit führende Plasmahersteller, musste aus Kostengründen die Belegschaft abbauen sowie mehrere Blutspendezentren schliessen. Ausserdem ist von Bayer bekannt, dass die Plasmasparte veräussert werden soll.


Ist wohl doch ein heiß umkämpfter Markt. ??!!
Und dann noch teilen !!
Was soll da unter dem Strich bleiben ?

[XQC]

...viel Geld!

[franzwerner]

--- für die Anderen !

[XQC]

die drin sind...
...und mich!

[XQC]

ach es tut so gut im recht zu sein...
hier was fuer welche die driin sind...

Yeah, I saw that. I loaded up a lot of shares of HMSL on the strength of VITX. Traders haven`t discovered HMSL as a company that can remove mad cow disease prions from the blood supply yet.
The special meeting is probably related to their previously released news. I think a deal is in place.

Hemosol Inc.
Special Meeting on January 22, 2004
12/8/03

On January 22, 2004, the Company will hold a Special Meeting.
The record date is December 15, 2003.

CONTACT:
Tel: [phone] HEMOSOL INC
Fax: [phone]

allen eine guten rutsch ins neue...
XQC

[XQC]

na bin wohl nur noch alleine hier... hier etwas ueber den 22 januar (uebersetzt):

Hemosol Inc., eine finanziell gestörte biopharmaceutical Firma, sagte gestern, daß es Aktionäre bittet, die Austeilung bis vier Million allgemeine Anteile bei einer speziellen Aktionärsversammlung an Jan. 22 zu genehmigen. Die Anteile konnten zu MDS Inc. gegen MDS herausgegeben werden, das einem $20-million Darlehen von der Bank von Neuschottland zu Hemosol garantiert, das versucht hat, sein Hemolink Blutersatzprodukt zu entwickeln. Analytiker sagten, daß ein klinischer Versuch des Produktes im März aus Sicherheit Gründen verschoben wurde. MDS besitzt z.Z. ein Interesse 14.2-per-cent an Hemosol oder 6.549.897 allgemeine Anteile; es würde ein Interesse 22.9-per-cent besitzen, wenn alle vier Million Anteile sofort ausgeübt wurden. Die Austeilung der Anteile würde die Kreditbürgschaft ergeben, die bis zum 12 Monaten verlängert wurde. Hemosol hatte 46.103.784 ausgegebene Aktien bei Dez. 12, 2003. Unter dem Antrag bis zu konnten zusätzliche 23.051.892 allgemeine Anteile als Teil der Privatplazierungen für spezielle B Aktienbezugsrechtsscheine, die zusätzlichen Ermächtigungen, die als Teil der Garantien geherausgeben wurden und die Zukunftfinanzierungen, gesagtes Hemosol herausgegeben werden. Dieses erfordert auch Aktionärzustimmung. Hemosol sagte auch, daß es einen Plan betrachtet, seine Anteile an einer Strecke eines neuen Anteiles für jede zwei alten Anteile zu einem neuen Anteil für jede vier alten Anteile zu vereinigen. Ein abschließendes Verhältnis hat, entsprechend dem Informationen Rundschreiben schon festgestellt zu werden, das gestern freigegeben wird. Hemosol sagte, daß eine Entscheidung, zum der Anteile umzustrukturieren vor Jan. 22, 2005 jederzeit getroffen werden könnte. Die Anteile von Hemosol fielen 4 Cents auf $1.76 auf der Toronto Börse. Die Direktoren sagten, daß die Fähigkeit, zusätzliche Privatplazierung Anteile herauszugeben Hemosol die Flexibilität gibt, die Beendigung der nicht-klinischen Analyse von Hemolink, die Zeit zu finanzieren, die, um Blut-in Verbindung stehende Herstellung Dienstleistungen zur Biotechnologie und zu den biopharmaceutical Unternehmen zur Verfügung zu stellen und Anwärter des neuen Produktes zu entwickeln erforderlich ist. _ d Austeilung von d Anteil sein auch benötigen für working Arbeitskapital und ander finanzieren Anforderung, Hemosol sagen.

weis nicht was ich davon halten soll, geht wohl nur noch darum ob man an hemolink glaubt oder nicht...
...so jetzt geh ich feiern und lass es so richtig krachen...
nochmals (hoffentlich) frohes neues allerseits...

[Big Charly]

Hemosol To Retain Nasdaq National Market Listing
TORONTO, Jan. 2 /CNW/ - Hemosol Inc. (NASDAQ: HMSL, TSX: HML) today
announced that it has received notice from a Nasdaq Listing Qualifications
Panel that it had regained compliance with The Nasdaq National Market`s
minimum bid price requirement by demonstrating a closing bid price on Nasdaq
of at least US$1.00 per share for the twelve consecutive business days ended
December 19, 2003. Accordingly, the Panel determined to continue the listing
of the Company`s common shares on Nasdaq.
"We are very pleased that our Nasdaq listing will continue as The Nasdaq
National Market is an important trading forum for our U.S. shareholders," said
Lee Hartwell, President & CEO Hemosol Inc.
The recent determination by the Panel follows a determination by Nasdaq
in October 2003 that the Company was not in compliance with the minimum bid
price of US$1.00 per share (which is a requirement for continued listing on
Nasdaq) and that the Company`s common shares were subject to delisting from
Nasdaq. At that time, the Company requested a hearing before the Panel to
request that it be given an additional six month period to achieve compliance
with the minimum bid price requirement based on Nasdaq`s proposed changes to
Marketplace Rule 4450(e)(2). Throughout the period, Hemosol`s common shares
remained listed and continued to be traded on Nasdaq.



Hemosol Retain Nasdaq Nationale Markt-Auflistung
TORONTO, Jan. 2 /CNW /-Hemosol Inc. (NASDAQ: HMSL, TSX,: HML) heute
verkündete, daß es Benachrichtigung von ein Nasdaq Auflistung Qualifikationen bekommen hat,
Tafel, daß es Fügsamkeit mit Dem Nasdaq Nationale Markt wiedererlangt hatte,
Minimum Angebot Preis Anforderung durch das Demonstrieren eines schließenden Angebot-Preises auf Nasdaq
von wenigstens US$1.00 pro Anteil für die zwölf aufeinanderfolgenden Unternehmen-Tage endete
Der 19. Dezember 2003. Dementsprechend bestimmte die Tafel, um die Auflistung fortzusetzen
von den gewöhnlichen Anteilen der Gesellschaft auf Nasdaq.
" Wir sind sehr gefallen, daß unsere Nasdaq Auflistung als Der Nasdaq fortsetzen wird,
Nationaler Markt ist ein wichtiges tauschendes Forum für unsere AMERIKANISCHEN Aktionäre, sagte "
Lee Hartwell, Präsident & CEO Hemosol AG
Die letzte Entschlossenheit durch die Tafel folgt einer Entschlossenheit von Nasdaq
in Oktober 2003, daß die Gesellschaft nicht in Fügsamkeit mit dem Minimum-Angebot war,
Preis von US$1.00 pro Anteil (welche ist eine Anforderung für fortgesetzte Auflistung auf
Nasdaq) und daß die gewöhnlichen Anteile der Gesellschaft dem Löschen von unterlagen,
Nasdaq. Zu dieser Zeit bat die Gesellschaft um ein Gehör vor der Tafel zu
Bitte, daß ihm eine zusätzliche sechs Monat-Periode gegeben würde, um Fügsamkeit zu erreichen,
mit der Minimum Angebot Preis Anforderung, die auf Nasdaq `s vorgeschlagenen Änderungen zu gegründet wird,
Marktplatz Regel 4450(e)(2). Überall in die Periode, Hemosol `s gewöhnliche Anteile
blieb aufgezählt und setzte fort, auf Nasdaq getauscht zu werden.

[j.f.]

bravo !! sehr aufschlußreich

[franzwerner]

Welcome in the pennys.

[XQC]

Hemosol Receives Final Receipt for Short Form Prospectus
Thursday January 15, 11:33 am ET


TORONTO, Jan. 15 /PRNewswire-FirstCall/ - Hemosol Inc. (NASDAQ: HMSL, TSX: HML) today announced that it has received a final receipt from the Ontario Securities Commission on behalf of the securities commissions in the Provinces of Ontario and Alberta for its short form prospectus.
This prospectus qualifies for distribution the common shares and warrants underlying the Series A special warrants and the Series B special warrants sold to investors by way of Hemosol`s previously announced private placement on November 28, 2003. The Series A special warrants and the Series B special warrants will be deemed exercised at 5:00 p.m. (EST) on January 22, 2004, provided that, in the case of the Series B special warrants, shareholder approval of the issuance of the common shares and warrants underlying the Series B special warrants is obtained at a special meeting of shareholders to be held on January 22, 2004.

[XQC]

cool so alleine hier...
is noch jemand das?
wenn ja, dann ist hier was zum lesen...


TODAY`S PAPER

Shareholders give Hemosol go-ahead

Approve share issue, consolidation so it can implement turnaround strategy

By LEONARD ZEHR
BIOTECHNOLOGY REPORTER
Friday, January 23, 2004 - Page B8

TORONTO -- Troubled Hemosol Inc. was thrown a lifeline yesterday as shareholders gave the drug developer permission to privately sell up to 23.1 million new shares or 50 per cent of the stock now outstanding to implement its turnaround strategy.

The new stock will allow Hemosol to complete a $5.9-million private sale of special warrants last November.

It will also allow Hemosol to issue, if necessary, up to four million warrants to MDS Inc. in exchange for MDS continuing to guarantee a $20-million loan from Bank of Nova Scotia to Hemosol until June, 2005.

Toronto-based MDS already holds a 14-per-cent stake in Hemosol as well as six million warrants related to the bank guarantee.

After the two transactions, Hemosol would still be entitled to privately issue just over 18 million new common shares to finance further analysis of its blood substitute product Hemolink, retool its plant to manufacture new blood-related biologic drugs for other companies and develop its product pipeline.

Last March, the safety of Hemolink, was thrown into question when it failed in tests with cardiac patients.

Chief executive officer Lee Hartwell said the company has no immediate plans to sell any new stock.

Shares of Hemosol gained 1 cent to $1.60 on the Toronto Stock Exchange yesterday after trading as high as $1.75.

Shareholders also gave the company the green light to consolidate its stock in a ratio between one-for-two and one-for-four during the next 12 months if its stock price falls below the minimum listing requirements of the Nasdaq Stock Market.

Mr. Hartwell said the recent $5.9-million sale of warrants was an "interim step in recapitalizing the company" as it pursues other alternatives to strengthen its balance sheet.

Among other things, he said the company was exploring the "non-dilutive monetization of our tax losses and refinancing our [manufacturing plant] around the Prometic/ARC alliance."

Hemosol`s tax-loss carry forwards were estimated at $185-million in mid-2003.

In December, the company joined forces with ProMetic Life Sciences Inc. of Montreal and the American Red Cross to retrofit its idle plant in Mississauga and establish the country`s first blood plasma plant for the production of valuable medical proteins.

Mr. Hartwell said Hemosol expects to begin generating revenue from the venture in early 2005.

[XQC]

ich habe noch nie einen so "bescheidenen" kursverlauf erlebt...
wenn eines keinen spass macht, dann diese aktie zu beobachten...
das gleiche gilt fuer dieses board!
eigentlich sollte man hier meinungen "austauschen", stattdessen bin ich hier alleinunterhalter...
...und das hat nun auch ein ende...

[aalerich]

hallo, es gibt doch noch user in diesem Forum !!!
Es ist ja in letzter Zeit ziemlich ruhig hier....
Charttechnisch gesehen mache ich da eine interessante
Wimpelformation aus - da scheint sich ja etwas anzu-
bahnen, oder ???

[aalerich]

Hat irgend jemand neue news ?
Wie sieht`s aus ?

[franzwerner]

Wie lautet eigentlich die Steigerungsform von tot ? (toter ??)

[franzwerner]

Es gibt sie doch, die Steigerungsstufe - LPBP Inc. (Labco)